NZ747693A - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors - Google Patents

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Info

Publication number
NZ747693A
NZ747693A NZ747693A NZ74769317A NZ747693A NZ 747693 A NZ747693 A NZ 747693A NZ 747693 A NZ747693 A NZ 747693A NZ 74769317 A NZ74769317 A NZ 74769317A NZ 747693 A NZ747693 A NZ 747693A
Authority
NZ
New Zealand
Prior art keywords
derivatives
riboside
nicotinic acid
nicotinamide
ribofuranosyl
Prior art date
Application number
NZ747693A
Other languages
English (en)
Inventor
Troy Rhonemus
Ryan Dellinger
Mark Morris
Aron Erickson
Hadi Cassier
Marie Migaud
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of NZ747693A publication Critical patent/NZ747693A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
NZ747693A 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors NZ747693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Publications (1)

Publication Number Publication Date
NZ747693A true NZ747693A (en) 2023-07-28

Family

ID=60088650

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ747693A NZ747693A (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Country Status (13)

Country Link
US (1) US10183036B2 (enExample)
EP (1) EP3445359B8 (enExample)
JP (3) JP7089480B2 (enExample)
KR (1) KR20190008246A (enExample)
CN (1) CN109640984A (enExample)
AU (2) AU2017254657A1 (enExample)
BR (1) BR112018071573A2 (enExample)
CA (1) CA3021571C (enExample)
ES (1) ES2948968T3 (enExample)
MX (1) MX393076B (enExample)
NZ (1) NZ747693A (enExample)
WO (1) WO2017184885A1 (enExample)
ZA (1) ZA201807736B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322419B1 (en) * 2015-07-15 2025-09-03 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EA035664B1 (ru) 2015-08-05 2020-07-23 МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
BR112019010607B1 (pt) 2016-11-29 2023-10-31 University Of Iowa Research Foundation Uso de precursores de nad e composição compreendendo os referidos precursores
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
AU2019214858B2 (en) * 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
JP2021525279A (ja) * 2018-05-22 2021-09-24 ジャンプスタート ファーティリティ ピーティーワイ リミテッド 抗加齢剤としてのニコチン酸リボシドのアミノ酸塩
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
CN113727987A (zh) * 2019-02-21 2021-11-30 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、还原型烟酰基核苷化合物和烟酰基核苷化合物衍生物在制品的用途
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
JP7610531B2 (ja) * 2019-06-05 2025-01-08 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド
EP3980028A1 (en) * 2019-06-05 2022-04-13 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating/preventing skeletal muscle disease
CN113840612A (zh) * 2019-06-05 2021-12-24 雀巢产品有限公司 用于治疗/预防肝脏疾病的还原型烟酰胺核糖核苷
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
US20230000888A1 (en) 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions
WO2021180732A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
WO2021180731A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
EP4117681A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
US20230095103A1 (en) * 2020-03-09 2023-03-30 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN115669929A (zh) * 2021-01-15 2023-02-03 江苏恒正合生命科学有限公司 辅助改善记忆的功能性食品其制备方法
US20240245714A1 (en) * 2021-05-05 2024-07-25 Societe Des Produits Nestle S.A. Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+)
KR20240020716A (ko) 2021-05-27 2024-02-15 메트로 인터내셔널 바이오테크 엘엘씨 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법
US20230014055A1 (en) * 2021-06-18 2023-01-19 Mitopower Llc Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
US20240415862A1 (en) * 2021-10-27 2024-12-19 Elysium Health Inc. Methods for treatment of menopausal syndromes
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
EP4472993A2 (en) * 2022-02-04 2024-12-11 Elysium Health, Inc. Ribose linkers and conjugates thereof
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7927859B2 (en) * 2003-08-22 2011-04-19 Rice University High molar succinate yield bacteria by increasing the intracellular NADH availability
AU2005211773B2 (en) 2004-02-10 2009-06-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
AU2005257883A1 (en) 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
EP3369738B1 (en) * 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
ES2925879T3 (es) * 2013-10-30 2022-10-20 Chromadex Inc Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel
KR20170008320A (ko) * 2014-06-06 2017-01-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도
MX390185B (es) * 2015-03-16 2025-03-20 Chromadex Inc Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
EP3322419B1 (en) 2015-07-15 2025-09-03 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EA035664B1 (ru) 2015-08-05 2020-07-23 МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+
US10857172B2 (en) * 2016-04-14 2020-12-08 Chromadex, Inc. Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development

Also Published As

Publication number Publication date
US10183036B2 (en) 2019-01-22
MX393076B (es) 2025-03-24
EP3445359A1 (en) 2019-02-27
JP2019514874A (ja) 2019-06-06
CA3021571C (en) 2023-01-03
WO2017184885A8 (en) 2023-08-24
JP7493007B2 (ja) 2024-05-30
WO2017184885A1 (en) 2017-10-26
US20170304338A1 (en) 2017-10-26
AU2022221384B2 (en) 2023-03-23
ES2948968T3 (es) 2023-09-22
EP3445359C0 (en) 2023-06-07
CN109640984A (zh) 2019-04-16
MX2018012849A (es) 2019-08-29
ZA201807736B (en) 2020-05-27
BR112018071573A2 (pt) 2019-02-12
KR20190008246A (ko) 2019-01-23
AU2022221384A1 (en) 2022-09-22
CA3021571A1 (en) 2017-10-26
EP3445359B1 (en) 2023-06-07
JP2021176871A (ja) 2021-11-11
EP3445359A4 (en) 2019-12-25
AU2022221384C1 (en) 2023-08-03
JP2023002685A (ja) 2023-01-10
JP7089480B2 (ja) 2022-06-22
AU2017254657A1 (en) 2018-11-15
EP3445359B8 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
NZ747693A (en) Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors
EA201890435A1 (ru) Производные никотинамидмононуклеотида и их применение
WO2020131578A3 (en) Nicotinyl riboside compounds and their uses
BR112012020742A2 (pt) derivados de pirazolo piperidina como inibidores de nadph oxidase.
MX2015005949A (es) Nucleosidos que contienen aza-azucar antiviral.
ZA202106912B (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
PL2007429T3 (pl) Doustna kompozycja o korzystnym działaniu sercowo-naczyniowym, zawierająca berberynę
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
TW200607804A (en) Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2010035219A3 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MY170437A (en) Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
MX2015008837A (es) Composiciones parenterales estables de dnj.
Endo et al. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
DOP2010000342A (es) Compuestos conteniendo nitrogeno triciclico y sus usos como antibacteriales
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
CY1108314T1 (el) Σκευασμα για στοματικη χορηγηση εχοντας μια δραση που προαγει την υγεια επι του καρδιαγγειακου συστηματος
WO2006072809A8 (en) Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions
AU2017241626A1 (en) Viable cell compositions, and methods related to same
CA3011436C (en) VANCOMYCIN-BASED FORMULATIONS
MX2025001193A (es) Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca
WO2024259359A3 (en) Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
BR112021024663A2 (pt) Composições e métodos que usam trigonelina para produzir nad+ intracelular
MX2012006287A (es) Activadores de azaindol glucocinasa.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250417